Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:

 

Liverpool to trial new pancreatic cancer therapy

16.03.2007
Patients in Liverpool are to trial a new therapy for pancreatic cancer – a disease which sees most sufferers die within a year of diagnosis.

One of the 10 most common cancers in the UK, it is among the most difficult to diagnose and treat and kills around 7,000 people each year. There are very few early symptoms so most patients present late and only around 15% are suitable for surgery – currently the only treatment available.

The Phase III TeloVac trial has been designed by the Pancreatic Cancer Clinical Sub-Group of the UK National Cancer Research Institute and will be run by Cancer Research UK’s Liverpool Cancer Trials Unit.

Funded by Cancer Research UK, the trial will test the vaccine GV1001 alongside two chemotherapy drugs gemcitabine and capecitabine on patients with locally advanced and metastatic pancreatic cancer. GV1001 is a new immunotherapeutic drug for pancreatic cancer developed by Danish-based biotech company Pharmexa.

One of the trial’s two principal investigators, Professor John Neoptolemos, based at the University of Liverpool and a consultant surgeon at the Royal Liverpool University Hospital, said: “The National Cancer Research Institute is very committed to this trial and is focusing a great deal of energy on recruiting patients to take part in it. This is because we firmly believe that GV1001 could play a key role in the future treatment of pancreatic cancer.”

He added: “We’re proud to manage this fundamental trial at the Liverpool Cancer Trials Unit and we hope other centres in the UK will participate in order to achieve maximum benefit for patients suffering from locally advanced and metastatic pancreatic cancer.”

“GV1001 is a particularly attractive vaccine; the antigen that it targets is expressed on virtually all pancreatic cancer cells and the vaccine stimulates the production of all of the cells that are required for an effective immune attack upon these cancers. Adding it to the platform of chemotherapy is an exciting strategy which, if successful, would create a new standard of care in this disease."

Professor John Toy, Medical Director at Cancer Research UK, said: “New treatments are desperately needed for pancreatic cancer as survival rates are so poor. GV1001 is a new generation of agent that harnesses the body’s own immune system to fight cancer. We are delighted to be funding a trial of such an innovative treatment.”

Patients with non-resectable pancreatic cancer will be randomly distributed into one of three arms of the trial:

• 370 patients will be treated with gemcitabine and capecitabine in a standard treatment

• 370 patients will be treated first with gemcitabine and capecitabine for eight weeks, following which they will be treated with GV1001

• 370 patients will be treated with gemcitabine and capecitabine and with GV1001 at the same time

The research team aims to find whether the patients treated with a combination of GV1001 and chemotherapy live longer than patients who only receive chemotherapy. It is not expected that GV1001 will cure patients, but that treatment will prolong their lives and that a small proportion of the patients may experience significantly longer survival.

Kate Spark | alfa
Further information:
http://www.liv.ac.uk

More articles from Health and Medicine:

nachricht Researchers identify cause of hereditary skeletal muscle disorder
22.02.2017 | Klinikum der Universität München

nachricht Second cause of hidden hearing loss identified
20.02.2017 | Michigan Medicine - University of Michigan

All articles from Health and Medicine >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: Breakthrough with a chain of gold atoms

In the field of nanoscience, an international team of physicists with participants from Konstanz has achieved a breakthrough in understanding heat transport

In the field of nanoscience, an international team of physicists with participants from Konstanz has achieved a breakthrough in understanding heat transport

Im Focus: DNA repair: a new letter in the cell alphabet

Results reveal how discoveries may be hidden in scientific “blind spots”

Cells need to repair damaged DNA in our genes to prevent the development of cancer and other diseases. Our cells therefore activate and send “repair-proteins”...

Im Focus: Dresdner scientists print tomorrow’s world

The Fraunhofer IWS Dresden and Technische Universität Dresden inaugurated their jointly operated Center for Additive Manufacturing Dresden (AMCD) with a festive ceremony on February 7, 2017. Scientists from various disciplines perform research on materials, additive manufacturing processes and innovative technologies, which build up components in a layer by layer process. This technology opens up new horizons for component design and combinations of functions. For example during fabrication, electrical conductors and sensors are already able to be additively manufactured into components. They provide information about stress conditions of a product during operation.

The 3D-printing technology, or additive manufacturing as it is often called, has long made the step out of scientific research laboratories into industrial...

Im Focus: Mimicking nature's cellular architectures via 3-D printing

Research offers new level of control over the structure of 3-D printed materials

Nature does amazing things with limited design materials. Grass, for example, can support its own weight, resist strong wind loads, and recover after being...

Im Focus: Three Magnetic States for Each Hole

Nanometer-scale magnetic perforated grids could create new possibilities for computing. Together with international colleagues, scientists from the Helmholtz Zentrum Dresden-Rossendorf (HZDR) have shown how a cobalt grid can be reliably programmed at room temperature. In addition they discovered that for every hole ("antidot") three magnetic states can be configured. The results have been published in the journal "Scientific Reports".

Physicist Dr. Rantej Bali from the HZDR, together with scientists from Singapore and Australia, designed a special grid structure in a thin layer of cobalt in...

All Focus news of the innovation-report >>>

Anzeige

Anzeige

Event News

Booth and panel discussion – The Lindau Nobel Laureate Meetings at the AAAS 2017 Annual Meeting

13.02.2017 | Event News

Complex Loading versus Hidden Reserves

10.02.2017 | Event News

International Conference on Crystal Growth in Freiburg

09.02.2017 | Event News

 
Latest News

Microhotplates for a smart gas sensor

22.02.2017 | Power and Electrical Engineering

Scientists unlock ability to generate new sensory hair cells

22.02.2017 | Life Sciences

Prediction: More gas-giants will be found orbiting Sun-like stars

22.02.2017 | Physics and Astronomy

VideoLinks
B2B-VideoLinks
More VideoLinks >>>